Lymphoma trial tests which chemo combo works best for younger patients

NCT ID NCT00498043

Completed Disease control Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested two different chemotherapy regimens (R-CHOP14 and R-ACVBP14), both combined with the drug rituximab, in 222 adults aged 18 to 59 with an aggressive type of B-cell lymphoma. The goal was to see which combination led to a complete response after four cycles of treatment. The trial also used PET scans to guide further treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rituximab combined with chemotherapy (R-CHOP14 or R-ACVBP14)
What this could lead to: If successful, this could help identify a more effective chemotherapy combination for younger adults with aggressive lymphoma, potentially improving remission rates.
What could go wrong: This is a Phase II trial with only 222 participants, so results may not apply to all patients. The study is completed, but the findings may not lead to a standard treatment change without further testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA, B-CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm diffuse large B-cell lymphoma lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA, B-CELL LYMPHOMA, LARGE-CELL, DIFFUSE

Contacts and locations

Locations

René Olivier Casasnovas

Dijon, 21000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.